AB 1990 Just Cleared Appropriations: Where the California GLP-1 Bill Stands Now
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
California Assembly Bill 1990 cleared the Assembly Appropriations Committee on May 14, 2026 by a 13 to 0 vote and is now waiting for a full Assembly floor vote, with amendments added in late April that narrowed some of the bill's advertising disclosure rules (California Legislative Information). If it passes, the bill would tighten ingredient, record keeping, and advertising rules for licensed pharmacies that compound GLP-1 weight loss medications in California, and the next few weeks will likely decide whether it becomes state law.
Who This Helps
This update is for you if you live in California and take a compounded GLP-1 medication, you are watching access and pricing closely, or you wrote in about AB 1990 the first time it came up and want to know where it stands now. It is also useful for patients in other states who want to see how a state compounding bill moves through the legislative process in real time.
Does This Affect Your GLP-1 Today?
If you are currently taking a compounded GLP-1 medication or a brand GLP-1 medication in California, nothing changes for you right now because AB 1990 has not become law (California Legislative Information). The bill is still moving through the California legislature and would need to clear the full Assembly, the Senate, and the Governor's desk before it would take effect. Your prescriber can still write a prescription, your licensed pharmacy can still fill it, and FDA-approved brand medications like Ozempic, Wegovy, Mounjaro, and Zepbound remain governed by federal approval and your insurance.
What Has Changed Since April
When we first wrote about AB 1990 in late April, the bill had just cleared the Assembly Business and Professions Committee on a 17 to 1 vote and was heading into its next committee (California Legislative Information). Three things have happened since.
On April 21, the bill cleared the Assembly Privacy and Consumer Protection Committee on a 15 to 0 vote, but only after the bill's authors agreed to amend the advertising disclosure language to address the opposition's intellectual property concerns (Assembly Privacy and Consumer Protection analysis). The amended bill text was filed on April 23.
On May 13, the Assembly Appropriations Committee placed the bill on its suspense file, which is California legislative shorthand for a holding spot used for bills with cost implications (California Legislative Information). The following day, on May 14, the same committee voted the bill out 13 to 0 with a do pass recommendation, sending it to the full Assembly floor.
The opposition coalition expanded over the same window. NetChoice, a trade association of internet companies, filed a formal letter of opposition on May 8 arguing that the bill is anticompetitive and mirrors legislation pushed in multiple states (NetChoice). The Alliance for Pharmacy Compounding published an opinion piece in Capitol Weekly on May 22 making a sharper version of the same case, written by the group's chief executive (Capitol Weekly).
What this means for you: the bill has gathered momentum and broader public opposition at the same time, and the next decisive moment is the full Assembly floor vote.
What the Late-April Amendments Actually Changed
The April 21 amendment changes one specific thing in the advertising section of the bill (Assembly Privacy and Consumer Protection analysis). The original draft required a compounded medication advertisement to disclose all of the potential side effects, contraindications, and warnings tied to the active ingredients used. The amended version requires those disclosures from the labeling of any FDA-approved drug that shares the same active ingredients, unless the advertiser can show that a particular disclosure is not relevant to the compounded preparation.
That change does two things. It responds to the opposition's argument that compounders cannot legally reuse the clinical trial data behind an FDA-approved drug's label. And it gives compounding pharmacies a path to argue that a specific warning does not apply to a specific preparation.
The rest of the bill stayed substantively the same. Licensed compounders preparing GLP-1 medications in California would have to use pharmaceutical-grade bulk ingredients with certificates of analysis from the supplier, source from FDA-registered facilities inspected within the last 2 years, conduct quality control testing on both the ingredient and the finished batch, keep records for at least 2 years past the medication's expiration date, and follow the new advertising disclosure rules (California Legislative Information). Penalties stay at $1,000 per dose plus potential license revocation by the California State Board of Pharmacy.
Against current practice: California compounding pharmacies already follow United States Pharmacopeia compounding chapters and California State Board of Pharmacy rules (California Business and Professions Code Section 4126.8). The bill formalizes a uniform documentation floor on top of those requirements specifically for GLP-1 compounding, and it codifies advertising rules that pull from recent FDA enforcement language on this kind of marketing (FDA).
Why the Opposition Has Grown
The public opposition coalition now includes the Alliance for Pharmacy Compounding, the California Pharmacists Association, the Chamber of Progress, and NetChoice (Assembly Privacy and Consumer Protection analysis). Their arguments cluster around four themes.
One is duplication. California already requires pharmacies to comply with United States Pharmacopeia compounding chapters 795, 797, and 800 alongside California State Board of Pharmacy oversight, and many of the bill's documentation requirements overlap with existing federal and state rules (Assembly Privacy and Consumer Protection analysis).
Another is selective scope. The bill applies to state-licensed pharmacies but does not apply to physician offices, med spas, or unregulated online sellers in the same way, even though the regulator has observed patient safety concerns in those less-regulated settings (Capitol Weekly).
A third is regulator discretion. The mandatory $1,000-per-dose fine and automatic license revocation structure removes the California State Board of Pharmacy's ability to weigh facts and apply proportional discipline, according to the Alliance for Pharmacy Compounding's chief executive (Capitol Weekly).
A fourth is competition. NetChoice has argued that AB 1990 functions as an anticompetitive measure that benefits the largest pharmaceutical companies by raising the cost of compounded alternatives and pushing patients toward higher-priced brand medications (NetChoice).
The bill's supporters frame it differently. Registered supporters include the California Life Sciences Association, the American Diabetes Association, Biocom California, the Partnership for Safe Medicines, and the National Hispanic Health Foundation (Assembly Privacy and Consumer Protection analysis). They point to FDA reports of more than 600 adverse event reports tied to compounded GLP-1 products by November 2024 (Journal of the Endocrine Society), to a 2025 analysis finding that nearly half of compounded GLP-1 marketing websites did not list warnings or contraindications, and that 36.7% claimed or implied FDA approval (Yale School of Medicine), and to FDA enforcement letters sent to 30 telehealth companies in early 2026 for misleading compounded GLP-1 advertising (FDA).
Both framings can hold weight at the same time, which is part of what makes the floor vote interesting. Real problems with misleading marketing and ingredient sourcing have been documented, and the bill's tools may not match those problems neatly.
What this means for you: either version of the story centers on how California regulates the pharmacy and the supply chain. Your prescription is downstream of that conversation.
Where the State's Pharmacy Regulator Comes Down
The state's own pharmacy regulator has weighed in on the bill. The Alliance for Pharmacy Compounding has reported that the California State Board of Pharmacy raised concerns after reviewing the legislation, flagging that mandatory penalties remove its discretion to evaluate facts and apply proportional discipline, and that the bill targets entities the Board already oversees while leaving higher-risk settings such as med spas and unregulated online sellers comparatively untouched (Capitol Weekly).
That regulator-level concern has not stopped the bill in committee. It is the kind of input, though, that can influence floor votes and Senate review, and it shows up in the testimony submitted to multiple committees (Assembly Privacy and Consumer Protection analysis).
What Happens Next
The bill now sits with the full California Assembly (California Legislative Information). A floor vote is the next significant step. If it passes the Assembly, it heads to the California Senate for its own committee process and floor vote, and then to the Governor for signature or veto. The 2025 to 2026 California legislative session runs through the middle of September, which leaves a fixed window for the rest of the bill's path. Amendments can still happen along the way, and the language has already shifted twice since the bill was first introduced.
If you want to follow this in real time, the California Legislative Information bill status page is updated within a day of each action and is the most reliable single source for what is happening with AB 1990.
Free Resources If You Want to Engage
A few options, none of which require an opinion you do not already have.
- Read our earlier explainer on AB 1990 for the original walkthrough of what the bill does, how it would affect 503A and 503B compounding pharmacies, and how it compares to similar legislation in other states.
- Read the actual bill text and the committee analyses for yourself at California Legislative Information, which lists every amended version side by side and includes the full committee write-ups (California Legislative Information).
- Send a message to your California Assembly member through the Alliance for Pharmacy Compounding's advocacy tool, which looks up your representative based on your address and provides a suggested message you can edit (Alliance for Pharmacy Compounding).
- Write your representative directly through the California State Assembly's general contact tools if you prefer to send your own message without going through an advocacy group (California State Assembly).
- Ask your prescriber and your pharmacy what they expect to change for their workflow if AB 1990 passes, since most California compounding pharmacies have already modeled the documentation impact.
GLP Winner is not affiliated with any of the external resources listed above. They are included as free, publicly available tools that may support your engagement with this bill.
Language to Watch For
Coverage and social media on both sides tends to overshoot. A few phrases worth slowing down on as the floor vote approaches:
- AB 1990 bans compounded GLP-1s in California. The current bill text raises ingredient, record keeping, and advertising standards without taking compounded products off the market (California Legislative Information). The effective ban framing comes from the practical concern that some pharmacies may exit the market under the new compliance burden, which is a separate argument made by opponents (NetChoice).
- AB 1990 is already California law. As of late May 2026, the bill has cleared three Assembly committees and is awaiting a full Assembly floor vote, with two more chambers and the Governor's signature still ahead before it would take effect (California Legislative Information).
- All compounded GLP-1s are unsafe. Compounded medications from licensed 503A and 503B pharmacies follow different rules than unregulated or grey market products, and the documented FDA enforcement issues with compounded GLP-1 products have largely tracked marketing language, ingredient sourcing concerns, and dosing errors with specific operators (FDA).
- The Board of Pharmacy supports this bill. As of the most recent public reporting, the state pharmacy regulator has raised concerns about the bill rather than endorsed it (Capitol Weekly).
Final Takeaway
AB 1990 is closer to a final vote than it has ever been, and the next month or two will decide whether the bill becomes California law. The version on the floor is narrower than the original draft after the late-April advertising amendments, and the opposition coalition has grown to include pharmacy, tech, and consumer groups, with the state's own pharmacy regulator reportedly raising concerns of its own.
For Californians on a compounded GLP-1 medication, nothing changes today. The steady move is to know who fills your prescription, ask your pharmacy what would change for them if the bill passes, and keep an eye on the next floor or Senate action.
For everyone else, this is one of the first major state compounding bills of its kind to reach a full floor vote, and the outcome will shape how other state legislatures approach the same question. Whichever way the vote goes, the patient side of the equation stays where it has always been: clear answers from your prescriber, transparent paperwork from your pharmacy, and the option to compare your full set of choices.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Lilly wants retatrutide classified as a biologic, but the FDA is not agreeing, now there is a lawsuit. What the lawsuit and OFA brief actually say.
Canada is approving generic Ozempic, India already has. Here is what it means for US prices, when patents expire, and what you can actually do today.
Starting July 1, 2026, Medicare Part D patients could get GLP-1s for $50/month. Here's who qualifies, what's covered, and what's still in motion.
Categories
Curated by
